Merck inks pact with 4 Indian drugmakers for HIV drug
Merck signed royalty-free, non-exclusive voluntary licensing agreements with four Indian drugmakers for manufacturing and supply of its once-monthly oral HIV pill Alimatravir for 129 low- and middle-income countries.
- Voluntary licensing is an agreement where the medicine originator allows other companies to make the drug under agreed terms to expand supply.
- Royalty-free means the licensed manufacturers may not pay royalty fees; non-exclusive means multiple manufacturers can be licensed rather than just one.
- Alimatravir is a once-monthly oral pill, meaning HIV patients may need dosing only once every month if the medicine is used as intended.
- Merck’s licensing uses Indian pharmaceutical companies to manufacture and supply the licensed generic to speed up access.
What happened (Merck, Indian partners, and Alimatravir licensing)
Merck signed royalty-free, non-exclusive voluntary licensing agreements with Indian pharmaceutical companies Aurobindo Pharma, Cipla, Emcure, and Viatris.
The licensing agreements are intended to enable manufacturing and supply of Merck’s investigational once-monthly oral HIV pill, Alimatravir.
UPSC can frame the issue around how voluntary licensing (royalty-free, non-exclusive agreements) can expand manufacturing capacity and reach for HIV medicines, especially in low- and middle-income countries. Students can connect licensing terms with access outcomes: speed of availability, supply continuity, and quality assurance in partner manufacturing.